Staurosporine-induced G2/M arrest in primary effusion lymphoma BCBL-1 cells

Ann Hematol. 2004 Dec;83(12):739-44. doi: 10.1007/s00277-004-0949-5. Epub 2004 Sep 25.

Abstract

Staurosporine, an inhibitor of protein kinase C, is a potential antitumor drug and its derivatives are used as anticancer drugs in clinical trials. Human herpesvirus 8 (HHV-8) is implicated in all forms of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), indicating it to be a DNA tumor virus. It is difficult to culture cell lines derived from KS patients; we therefore used a cell line derived from PEL (BCBL-1) to investigate whether staurosporine affects the HHV-8-related tumors. Our results show that staurosporine treatment reduces the cell viability of BCBL-1 cells and causes cell cycle arrest in the G2/M phase. The G2/M arrest was associated with the decrease in the expression of Cdc2 and cyclin B. Furthermore, the induction of the HHV-8 lytic cycle was not observed under the staurosporine treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CDC2 Protein Kinase / metabolism
  • Castleman Disease / drug therapy
  • Castleman Disease / pathology
  • Castleman Disease / virology
  • Cell Division / drug effects*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cyclin B / metabolism
  • DNA Viruses / metabolism
  • Enzyme Inhibitors / pharmacology*
  • G2 Phase / drug effects*
  • Herpesvirus 8, Human*
  • Humans
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, B-Cell / metabolism
  • Lymphoma, B-Cell / pathology
  • Lymphoma, B-Cell / virology
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism
  • Sarcoma, Kaposi / drug therapy
  • Sarcoma, Kaposi / pathology
  • Sarcoma, Kaposi / virology
  • Staurosporine / pharmacology*
  • Virus Replication / drug effects

Substances

  • Cyclin B
  • Enzyme Inhibitors
  • Protein Kinase C
  • CDC2 Protein Kinase
  • Staurosporine